Ariad: Worth Watching As Its Pipeline Matures
This article was originally published in The Pink Sheet Daily
Executive Summary
On the verge of getting its first chance at being a commercialization company, Ariad has lofty plans to become a global leader in oncology.
You may also be interested in...
Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q4 2011
Biopharmaceutical company financings more than doubled to $2.7 billion from Q3. There were 23 acquisitions bringing in a total of $17.7 billion. And in alliances there was a focus on biosimilars, oncology and neurology deals, and unique partnerships with clear paths to exits.
Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)
R&D head reflects on the accelerated approval program in the wake of FDA's February meeting with ODAC.
Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson (Part 1 Of 2)
R&D head talks about the company's lead candidate ponatinib's developmental plan under accelerated approval.